← All trials
NCT04243083
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 26, 2020
- Primary completion
- Jul 31, 2020
- Completion date
- Aug 10, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 84
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Hangzhou Highlightll Pharmaceutical Co., LtdLead sponsor
- Frontage Laboratories, Inc.Study director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.